1. Using PI3K Inhibitors for Relapsed/Refractory CLL and Follicular Lymphoma

2. FDA-Approved PI3K Inhibitors for CLL and FL

3. Idelalisib Registration Trial for R/R FL (101-09)

4. 101-09: Best Overall Response

5. 101-09: Other Key Efficacy Endpoints

6. 101-09: Efficacy in Early Relapsed FL Subset

7. 101-09: Most Common Grade 3/4 AEs

8. Idelalisib Registration Trial for R/R CLL (116)

9. Study 116: Overall Response Rate

10. Study 116: Progression-Free Survival

11. Study 116: Overall Survival

12. Common Toxicities Associated With Idelalisib

13. Copanlisib Registration Trial for R/R FL: CHRONOS-1

14. CHRONOS-1: ORR

15. CHRONOS-1: Other Key Efficacy Endpoints

16. CHRONOS-1: Most Common Grade > 3 AEs

17. Duvelisib Registration Trial for R/R CLL: DUO

18. DUO: PFS

19. DUO: PFS in Patients with ≥ 2 Prior Therapies

20. DUO: Lymph Node Responses

21. Duvelisib Registration Trial for R/R FL: DYNAMO

22. DYNAMO: Efficacy Results

23. Common Toxicities Associated With Duvelisib

24. AE Management Strategies

25. AE Management Strategies (cont)

26. Current Challenges/Unanswered Questions

27. Goals and Future Directions

28. Conclusions

29. Abbreviations